Molecular Mechanisms of Chemoradiotherapy Resistance in Esophageal Cancer and Clinical Response Strategies: From the Tumor Microenvironment to Precision Medicine

Yujiao Sun

doi:10.54097/d75j2e80

Authors

Yujiao Sun

DOI:

https://doi.org/10.54097/d75j2e80

Keywords:

Esophageal cancer, Chemoradiotherapy resistance, Tumor microenvironment, Precision therapy, Metabolic intervention.

Abstract

Esophageal squamous cell carcinoma (ESCC) is the sixth leading cause of cancer-related deaths globally, with more than half of cases occurring in China. Although chemoradiotherapy (CRT) is a major treatment modality for ESCC, its efficacy is often limited by tumor resistance. The 5-year survival rate of esophageal cancer patients is less than 30%, and the prognosis is poor. The mechanisms of induced resistance in cancer mainly include multi-dimensional factors such as the regulation of the tumor microenvironment (TME), the metabolic reprogramming of cancer-associated fibroblasts (CAFs), and the imbalanced proliferation of cancer stem cells. New strategies are urgently needed to break through this bottleneck. The study primarily focuses on reviewing the regulation of the tumor microenvironment, abnormal drug metabolism and transport, epigenetic modifications, and signaling pathways, aiming to reveal the mechanisms of CRT resistance, summarize strategies to overcome CRT resistance, and explore new treatment strategies such as targeted therapy and immunotherapy combination. This review emphasize the importance of multidisciplinary collaboration and individualized treatment to improve the cure rate and survival of ESCC patients.

Downloads

Download data is not yet available.

References

[1] Deboever N. Advances in diagnosis and management of cancer of the esophagus [J]. BMJ. 2024, 385: e074962.

[2] Zheng Rongshou, Chen Ru, Han Bingfeng, et al, Cancer incidence and mortality in China, 2022 [J]. Zhonghua Zhong Liu Za Zhi. 2024, 46 (3): 221-231.

[3] Li Rongyang, Huang Bing, Tian Hui, et al Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. [J] Front Oncol. 2023; 12: 1096717.

[4] An Lingbo, Li Mingyang, Jia Qingge. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma [J]. Mol Cancer. 2023, 22 (1):140.

[5] Wang Siliang, Kell V V, Zheng Miaomiao, et al. High antigen-presenting CAF levels correlate with reduced glycosaminoglycan biosynthesis-heparan sulfate/heparin metabolism in immune cells and poor prognosis in esophageal squamous cell carcinoma: Insights from bulk and single-cell transcriptome profiling [J]. Int J Biol Macromol. 2025, 301: 140418.

[6] Chen Jie, WangYan, Zhang Weiming, et al. NOX5 mediates the crosstalk between tumor cells and cancer-associated fibroblasts via regulating cytokine network [J]. Clin Transl Med. 2021, 11 (8): e472.

[7] Chen Xinjie, Cheng Guoyu, Zhu Liang, et al. Alarmin S100A8 imparts chemoresistance of esophageal cancer by reprogramming cancer-associated fibroblasts [J]. Cell Rep Med. 2024, 5 (6): 101576.

[8] Ren Qianhe, Zhang Pengpeng, Xiao Zhang, et al. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer [J]. Front Immunol. 2023, 14: 1199040.

[9] Li Hongmu, Miao Yu, Zhong Leqi, et al. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation [J]. Front Immunol. 2023, 14: 1162032.

[10] Han Tianci, Guo Xiaoqi, Xie Junwei, et al. SUMO modified ETV1 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by facilitating CCL2 transcription in esophageal squamous cell carcinoma cells [J]. Cancer Immunol Immunother. 2025, 74 (3): 87.

[11] Fan Jingyi, Kenneth K W T, Chen Zhe-Sheng, et al. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance. Drug Resist Updat. 2023 Jan; 66: 100905.

[12] Ji Gang, Yang Qi, Wang Song, et al. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma [J]. Genome Med. 2024, 16 (1): 49.

[13] Wang Renfeng, Huang Zhiliang, Lin Zhenyang, et al. Hypoxia-induced RBBP7 promotes esophagus cancer progression by inducing CDK4 expression [J]. Acta Biochim Biophys Sin (Shanghai). 2022, 54 (2): 179-186.

[14] Wang Miao, Chen Huan, He Xu, et al. Artemisinin inhibits the development of esophageal cancer by targeting HIF-1α to reduce glycolysis levels [J]. J Gastrointest Oncol. 2022, 13 (5): 2144-2153.

[15] Li Zhao, Chen Xi, Li Yongkang, et al. Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma and its Clinical Implications in Systemic Chemotherapy [J]. Int J Med Sci. 2025, 22 (4): 1002-1014.

[16] Chang WL. Nutlin-3 acts as a DNA methyltransferase inhibitor to sensitize esophageal cancer to chemoradiation [J]. Mol Carcinog. 2023, 62 (2): 277-287.

[17] Kuo IY. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes [J]. J Biomed Sci. 2019, 26 (1): 20.

[18] Guldenpfennig C. NF-kB's contribution to B cell fate decisions [J]. Front Immunol. 2023; 14: 1214095.

[19] Shi Ni, Yu Hao, Chen Tong. Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway [J]. Onco Targets Ther. 2019 Sep 17; 12: 7637-7647.

[20] Jin Yuan, Meng Qilin, Zhang Bihui, et al. Cancer-associated fibroblasts-derived exosomal miR-3656 promotes the development and progression of esophageal squamous cell carcinoma via the ACAP2/PI3K-AKT signaling pathway [J]. Int J Biol Sci. 2021, 17 (14): 3689-3701.

[21] Tanigawa K. S100A8/A9 Induced by Interaction with Macrophages in Esophageal Squamous Cell Carcinoma Promotes the Migration and Invasion of Cancer Cells via Akt and p38 MAPK Pathways [J]. Am J Pathol. 2022, 192 (3): 536-552.

[22] Paiboonrungruang C. Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia [J]. Redox Biol. 2023, 67: 102901.

[23] Yang Hui, Zhang Qiannan, Xu Miao, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis [J]. Mol Cancer. 2020, 19 (1): 41.

[24] Konnerth D. Targeted RT study: results on early toxicity of targeted therapies and radiotherapy [J]. Radiat Oncol. 2024; 19 (1): 113.

[25] Xie Liangyun, Zhang Zhi. Survival benefit of combined immunotherapy and chemoradiotherapy in locally advanced unresectable esophageal cancer: an analysis based on the SEER database [J]. Front Immunol. 2024, 16; 15: 1334992.

[26] Li Ming-Yang, Fan Lin-Ni, Han Dong-Hui, et al. Ribosomal S6 protein kinase 4 promotes radioresistance in esophageal squamous cell carcinoma [J]. J Clin Invest. 2020, 130 (8): 4301-4319.

[27] Liu Lu-Xin, Heng Jing-Hua, Deng Dan-Xia, et al. Sulconazole Induces PANoptosis by Triggering Oxidative Stress and Inhibiting Glycolysis to Increase Radiosensitivity in Esophageal Cancer. Mol Cell Proteomics. 2023 Jun; 22 (6): 100551.

[28] Guo Dongli, Jin Jing, Liu Jianghui, et al. Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A [J]. Drug Des Devel Ther. 2022, 16: 2423-2436.